The University of Texas Health Science Center at Houston (UTHSC-H), The University of Texas M.D. Anderson Cancer Center (UT MDACC), and the Memorial Hermann Hospital System wish to renew their Clinical and Translational Science Award (CTSA), which established the Center for Clinical and Translational Sciences (CCTS) in 2006. In the first cycle, the institutions created our CCTS, provided services to 835 investigators in 104 fields, trained KL2 scholars and TL1 trainees, and worked with the greater Houston and Brownsville communities to disseminate health care information and study the unique health issues in Brownsville's Hispanic border population. To further collaborative research in Texas, our CCTS founded the Texas CTSA Consortium and the Lowering the Barriers Program, which has established IRB reciprocity in the University of Texas System. Our CCTS's mission reads: The Center for Clinical and Translational Sciences provides research infrastructure, training and knowledge transfer to expedite the process of translating discovery to practice. We faciliate research and its dissemination for our investigators, our trainees and students, our patients, our local and state population, our Texas CTSA consortium collaborators, and the national CTSA consortium. To this end, we will focus on a thematic structure in the next cycle. Our themes are: 1) Advancing Translational Sciences by Advancing Personalized Therapy (T1 translation) by determing pathophysiology and developing targeted therapeutics and Advancing Community Engagement and dissemination and implementation research (T3/T4 translation);2) Advancing Clinical Sciences by accelerating and improving new modalities for the design and conduct of clinical research and by accelerating and improving outcomes of research (T2 translation);and 3) Advancing the Clinical and Translational Science Research Workforce (Post-graduate training. Graduate training and research staff training).

Public Health Relevance

The goal of the Center for Clinical and Translational Sciences (CCTS), funded by a Clinical and Translational Science Award, is to move scientific and medical discoveries as fas as possible from the laboratory to the clinic and community, where they can improve the health of the American people. The CCTS trains researchers, provides research services, and works with its communities to learn their helath concerns and spread health care information.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
3UL1TR000371-08S1
Application #
8918057
Study Section
Special Emphasis Panel (ZRR1-CR-1 (01))
Program Officer
Merchant, Carol
Project Start
2006-07-01
Project End
2017-05-31
Budget Start
2014-09-09
Budget End
2015-03-08
Support Year
8
Fiscal Year
2014
Total Cost
$115,500
Indirect Cost
$40,500
Name
University of Texas Health Science Center Houston
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771594
City
Houston
State
TX
Country
United States
Zip Code
77225
Gao, Zhanguo; Daquinag, Alexes C; Su, Fei et al. (2018) PDGFR?/PDGFR? signaling balance modulates progenitor cell differentiation into white and beige adipocytes. Development 145:
Dembla, Vikas; Somaiah, Neeta; Barata, Pedro et al. (2018) Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget 9:33232-33243
Briggs, Neima; Wei, Junfei; Versteeg, Leroy et al. (2018) Trichuris muris whey acidic protein induces type 2 protective immunity against whipworm. PLoS Pathog 14:e1007273
Rahbar, Mohammad H; Lee, MinJae; Hessabi, Manouchehr et al. (2018) Harmonization, data management, and statistical issues related to prospective multicenter studies in Ankylosing spondylitis (AS): Experience from the Prospective Study Of Ankylosing Spondylitis (PSOAS) cohort. Contemp Clin Trials Commun 11:127-135
Dong, Xiaomin; Cuevas-Diaz Duran, Raquel; You, Yanan et al. (2018) Identifying Transcription Factor Olig2 Genomic Binding Sites in Acutely Purified PDGFR?+ Cells by Low-cell Chromatin Immunoprecipitation Sequencing Analysis. J Vis Exp :
Fujii, Takeo; Matsuda, Naoko; Kono, Miho et al. (2018) Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer. Eur J Cancer 89:64-71
Herbrich, Shelley M; Kannan, Sankaranarayanan; Nolo, Riitta M et al. (2018) Characterization of TRKA signaling in acute myeloid leukemia. Oncotarget 9:30092-30105
Wang, Jing; Cai, Chunyan; Padhye, Nikhil et al. (2018) A Behavioral Lifestyle Intervention Enhanced With Multiple-Behavior Self-Monitoring Using Mobile and Connected Tools for Underserved Individuals With Type 2 Diabetes and Comorbid Overweight or Obesity: Pilot Comparative Effectiveness Trial. JMIR Mhealth Uhealth 6:e92
Subbiah, V; Velcheti, V; Tuch, B B et al. (2018) Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol 29:1869-1876
Brusco, Lauren L; Wathoo, Chetna; Mills Shaw, Kenna R et al. (2018) Physician interpretation of genomic test results and treatment selection. Cancer 124:966-972

Showing the most recent 10 out of 683 publications